Sidley is representing Tempest Therapeutics, Inc., a privately held, clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, in its merger with Millendo Therapeutics, Inc., in an all-stock transaction.
The combined company will focus on advancing Tempest’s oncology pipeline of small molecule therapeutics that have the potential to address a wide range of tumors. Upon shareholder approval, the combined company is expected to operate under the name Tempest Therapeutics and trade on the Nasdaq Capital Market under the ticker symbol TPST.
The Sidley team was led by Asher Rubin, Rob Carlson (M&A), and Frank Rahmani (Emerging Companies), and included Istvan Hajdu (Capital Markets); Nick DeAngelis and BinQuan Zhuang (M&A); Matthew Johnson and Li Wang (Employee Benefits); Rachel Kleinberg and Marianne Tassone (Tax); Jim Ducayet (Securities and Shareholder Litigation); and Torrey Cope and Carlo Felizardo (FDA).
